HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adjuvant vaginal high-dose-rate afterloading alone in endometrial carcinoma: patterns of relapse and side effects following low-dose therapy.

AbstractOBJECTIVE:
This retrospective study was conducted to document the incidence and location of recurrences as well as the rate of side effects following low-dose postoperative high-dose-rate (HDR) brachytherapy in patients with endometrial carcinoma.
METHODS:
From 1987 to 1993, 122 patients with moderate-risk (78) and high-risk (44) endometrial carcinoma underwent adjuvant vaginal irradiation. All patients received three fractions of 7 Gy specified on the surface of the vaginal cylinder.
RESULTS:
Relapses occurred in 12 (9. 8%) patients on average after 25.6 months. Seven (5.7%) patients had a sole pelvic recurrence; in 2 (1.6%) of those the relapse was located in the vagina only. Three (2.5%) patients had a pelvic relapse combined with distant metastases. Distant metastases alone were diagnosed in 2 (1.6%) patients. A tumor recurrence was diagnosed in 3 of 78 (3.8%) patients with moderate-risk disease and in 9 of 44 (20.5%) patients with high-risk disease. The estimated 5-year relapse-free survival was 94% for patients with moderate-risk and 74% for patients with high-risk tumors (P = 0.004). Neither severe nor chronic complications were noted.
CONCLUSION:
Even low doses of HDR brachytherapy seem sufficient for excellent vaginal disease control in moderate-risk disease. In advanced tumors combined radiation therapy is warranted for improved pelvic disease control.
AuthorsE Weiss, P Hirnle, H Arnold-Bofinger, C F Hess, M Bamberg
JournalGynecologic oncology (Gynecol Oncol) Vol. 71 Issue 1 Pg. 72-6 (Oct 1998) ISSN: 0090-8258 [Print] United States
PMID9784322 (Publication Type: Journal Article)
CopyrightCopyright 1998 Academic Press.
Topics
  • Aged
  • Aged, 80 and over
  • Brachytherapy (adverse effects, methods)
  • Endometrial Neoplasms (mortality, pathology, radiotherapy)
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Metastasis (pathology)
  • Neoplasm Recurrence, Local (pathology)
  • Radiotherapy, Adjuvant (adverse effects)
  • Retrospective Studies
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: